AstraZeneca PLC (STO:AZN)
1,642.00
+28.00 (1.73%)
Nov 10, 2025, 5:29 PM CET
AstraZeneca Employees
AstraZeneca had 94,300 employees as of December 31, 2024. The number of employees increased by 4,400 or 4.89% compared to the previous year.
Employees
94,300
Change (1Y)
4,400
Growth (1Y)
4.89%
Revenue / Employee
5.81M SEK
Profits / Employee
939.18K SEK
Market Cap
2.51T
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 94,300 | 4,400 | 4.89% |
| Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
| Dec 31, 2022 | 83,500 | 400 | 0.48% |
| Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
| Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Medicover AB | 47,256 |
| Getinge AB | 11,791 |
| Nolato AB | 5,837 |
| Elekta AB | 4,556 |
| Asker Healthcare Group AB | 4,030 |
| AddLife AB | 2,181 |
| Swedish Orphan Biovitrum AB | 1,806 |
| Sectra AB | 1,296 |
AstraZeneca News
- 7 hours ago - AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial - Benzinga
- 7 hours ago - AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial - Benzinga
- 13 hours ago - AstraZeneca (AZN) Earns FDA Orphan Drug Status for Leukemia Treatment - GuruFocus
- 1 day ago - AstraZeneca's Baxdrostat Achieves Major Breakthrough In Hypertension Treatment In Phase III Trial - Nasdaq
- 1 day ago - AstraZeneca (AZN) Announces Successful Phase III Trial Results for Baxdrostat - GuruFocus
- 1 day ago - Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial - Business Wire
- 1 day ago - Top global stories this week: Diageo, Novo Nordisk, AstraZeneca among notable names - Seeking Alpha
- 2 days ago - AstraZeneca PLC 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha